Secures EUR 10M Grant from Bpifrance to Support Clinical Development of OVX836, a Broad-Spectrum Influenza Vaccine
Summary
Osivax will apply the funds to prepare OVX836 for a Phase 2b field efficacy clinical trial to assess its efficacy against a broad range of circulating strains.We are deeply appreciative of the level of trust bestowed upon our approach from the French government and view this additional non-dilutive funding from Bpifrance as a validation to our novel pan-influenza approach. We are now well-positioned to accelerate the development of OVX836 through a large field efficacy trial, a critical milestone toward providing an improved influenza vaccine against currently circulating and emerging strains, commented Alexandre Le Vert, CEO and Co-Founder of Osivax.Supporting Osivax in the development of its innovative broad-spectrum influenza vaccine is a critical part of our efforts to advance French biomedical research and ensure our ability to effectively fight against ongoing and future infectious diseases, added Jeremy Berthuin, Health Sector Manager for Bpifrance. We look forward to the progress Osivax will make as it propels OVX836 through the next stages of clinical development.Osivax influenza vaccine, OVX836 targets the nucleoprotein (NP), a highly conserved internal antigen. Osivax oligoDOM\xae technology enables the design and production of recombinant version of the NP which self-assembles into a nanoparticle, thus triggering powerful T-and B-cell immune responses. OVX836 has shown promising safety, immunogenicity, and efficacy in preclinical and clinical trials (Phase 1 and Phase 2a) and continues to be evaluated in additional studies.Osivax is a biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM\xae, to transform current and new vaccines by generating superior T-cell responses in addition to strong and sustained B cell responses against highly mutating viruses.